Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Marzo 2024 - 3:00PM
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on
March 10, 2024, the Compensation Committee of its Board of
Directors granted inducement equity grants covering an aggregate of
51,600 shares of its common stock to four new employees, consisting
of inducement stock options to purchase an aggregate of 25,000
shares of common stock and inducement restricted stock units, or
RSUs, covering an aggregate of 26,600 shares of its common stock.
These inducement stock options and inducement RSUs are subject to
the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”),
but were granted outside of the 2018 Plan and were granted as
inducements material to the new employees entering into employment
with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
$7.99 per share, the closing price of Travere’s common stock on the
next trading day following the date of grant, are non-qualified
stock options, have a 10-year term and vest over four years, with
25% of the shares vesting on the one-year anniversary of the grant
date and the remaining 75% of the shares vesting in equal monthly
installments over the following 36 months, subject to the new
employee’s continued service relationship with Travere through the
applicable vesting dates.
The RSUs vest over four years, with 25% of the
shares vesting on each anniversary of the grant date, subject to
the new employee’s continued service relationship with Travere
through the applicable vesting dates.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for
life. We are a biopharmaceutical company that comes together every
day to help patients, families, and caregivers of all backgrounds
as they navigate life with a rare disease. On this path, we know
the need for treatment options is urgent – that is why our global
team works with the rare disease community to identify, develop,
and deliver life-changing therapies. In pursuit of this mission, we
continuously seek to understand the diverse perspectives of rare
patients and to courageously forge new paths to make a difference
in their lives and provide hope – today and tomorrow. For more
information, visit travere.com.
Contact Info
Media: |
Investors: |
888-969-7879 |
888-969-7879 |
mediarelations@travere.com |
IR@travere.com |
Travere Therapeutics (NASDAQ:TVTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Travere Therapeutics (NASDAQ:TVTX)
Gráfica de Acción Histórica
De May 2023 a May 2024